What is CROVALIMAB used for?

CROVALIMAB (brand name Piasky) is a Other indicated for See full prescribing information.

What are the most common side effects of CROVALIMAB?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for CROVALIMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is CROVALIMAB the same as Piasky?

Piasky is a brand name for CROVALIMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

CROVALIMAB

Q: How does CROVALIMAB work?

CROVALIMAB works through the following mechanism: 12.1 Mechanism of Action Crovalimab-akkz is a monoclonal antibody that specifically binds with high affinity to the complement protein C5, inhibiting its cleavage into C5a and C5b, preventing the formation of the membrane attack complex (MAC). Crovalimab-akkz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH..

Other

Brand names: Piasky

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Crovalimab-akkz is a monoclonal antibody that specifically binds with high affinity to the complement protein C5, inhibiting its cleavage into C5a and C5b, preventing the formation of the membrane attack complex (MAC). Crovalimab-akkz inhibits terminal complement-mediated intravascular hemolysis in patients with PNH.

Indications

See full prescribing information

FDA Warnings

5 WARNINGS AND PRECAUTIONS Type III hypersensitivity reactions: Monitor patients switching from another C5 inhibitor to PIASKY or from PIASKY to another C5 inhibitor as they are at risk of Type III hypersensitivity reactions related to the formation of drug-target-drug complexes ( 5
3 ) Other Infections: PIASKY can increase susceptibility to serious infections especially those caused by encapsulated bacteria
1 Serious Meningococcal Infection PIASKY, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (meningococcemia and/or meningitis) in any serogroup, including non-groupable strains
Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors

Known Side Effects

4 documented side effects by frequency

Fever

>10%

UTI

0.1-1%

Drug Not Working

0.1-1%

Joint Pain

0.1-1%

Community Discussions

No community discussions found for CROVALIMAB yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → CROVALIMAB openFDA label JSON → CROVALIMAB FAERS adverse-event reports → CROVALIMAB ClinicalTrials.gov → completed Phase 2+ trials of CROVALIMAB

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Subcutaneous